Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linaclotide Lactation Study
NCT02220348Phase 1Completed
- Sponsor
- Forest Laboratories
- Start
- Jul 2014
- Primary completion
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of linaclotide in irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC), sponsored by Forest Laboratories. Primary endpoint: Amount of linaclotide and its active metabolite (MM-419447) excreted in breast milk. Started Jul 2014; status: completed.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)chronic idiopathic constipation (CIC)
Beyond the preview
Go deeper on NCT02220348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02220348.